logo-loader
viewLuminex Resources

Luminex Resources continues to expand Camp zone at Condor project

The firm said current drilling had delineated a mineralized zone of variable width over a strike length of 300 metres and vertical depth of 400 metres

Luminex Resources -
Luminex told investors Monday it had sunk 18 holes and is continuing step-out drilling on mineralized intercepts

Luminex Resources Corp (CVE:LR) (OTCMKTS:LUMIF) continues to extend the Camp zone at its Condor project in southeast Ecuador via drilling. 

In a statement on Thursday, the company said current drilling had delineated a mineralized zone of variable width over a strike length of 300 metres and vertical depth of 400 metres. 

Extends mineralization to the southeast

Luminex has sunk around 7,600 metres so far in 18 holes and is continuing step-out drilling on mineralized intercepts, while a third rig has begun at the property.

One hole hit a second high-grade zone of mineralization below 600 metres (m). Highlight intercepts were 19.3 m of 6.1 grams per ton (g/t) gold and 36.3 g/t silver, including 0.9 m at 60.50 g/t gold and 299.0 g/t silver.

Luminex also said it had extended mineralization to the southeast and infilled the known zone above 400 metres.

Highlight assays here included 24.5m of 4 g/t gold and 10.2 g/t silver. Another hole showed 6 m at 4.2 g/t gold and 4.9 g/t silver and 9 m of 3.1 g/t gold and 12.3 g/t silver.

Condor lies 31 km south of the 9.5 million ounce gold Fruta del Norte project and 55 km south of Ecuacorriente's 4 million ounce gold Mirador project.

It has a 43-101 indicated gold resource of 1.4 million ounces, indicated silver of 9.2 million ounces and 43 million pounds of indicated copper.

Contact the author at [email protected]

Quick facts: Luminex Resources

Price: - -

TSX:LR
Market: TSX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

30 minutes ago

2 min read